Unicentric Castleman’s Disease Masquerading as Retroperitoneal Sarcoma—Two Paraneoplastic Presentations of a Rare Disease

Muralee, Madhu; Abdulla, Faheem Ahmed; Bharath, V

doi:10.1007/s13193-020-01072-z

Cited by 1 publication

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In fact, many cases of retroperitoneal Castleman disease in the literature were labeled as sarcomas preoperatively due to their similar appearance on US and CT imaging. 22–24 Notably, the inflammatory variant of WDL – also termed “lymphocyte-rich liposarcoma” – is a rare entity, whose histopathological similarities with Castleman disease, may serve as a diagnostic pitfall for the pathologist. 25 It comprises 2% of all liposarcomas and the majority of the cases have been described in the retroperitoneum with few cases also described in the thigh, pleura, scrotum and spermatic cord.…”

Section: Discussionmentioning

confidence: 99%

Castleman Disease with MDM2/CDK4 Protein Expression: a Potential Mimic of Inflammatory Variant of Liposarcoma with Significant Consequences

et al. 2022

View full text Add to dashboard Cite

Castleman disease is a rare benign lymphoproliferative disorder that includes a spectrum of distinct histopathological entities. The differential diagnosis of Castleman disease is broad and includes lymphomas, HIV-related lymphadenopathy, autoimmune disorders, and inflammatory liposarcoma. When Castleman disease occurs in the retroperitoneum, the distinction from the inflammatory variant of well-differentiated liposarcoma can be very challenging in small biopsies. Herein we report a case of Castleman disease that presented as a retroperitoneal mass and expressed MDM2 and CDK4 by immunohistochemistry. To our knowledge, this is the first report of Castleman disease staining positively for MDM2/CDK4, and it underscores how immunohistochemistry can potentially serve as a pitfall when differentiating this rare entity from retroperitoneal sarcomas.

show abstract

Section: Discussionmentioning

confidence: 99%